Mylan Says on October 10, Co, Meda Pharmaceuticals Got Notice CMA Was Opening Investigation for Possible Infringement of Competition Act 1998, Article 101 Of TFEU, With Respect to Alleged Agreements Related to Nefopam, a Product from Meda's Portfolio